Literature DB >> 28190094

Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?

Jasmina Mallet1,2,3, Nicolas Ramoz4,5, Yann Le Strat6,7,4, Philip Gorwood4,5,8, Caroline Dubertret6,7,4.   

Abstract

Cannabis use is associated with an increased risk of schizophrenia, and is considered to impact late neurodevelopment. Neurological soft signs (NSS) associated with schizophrenia are considered as markers of early neurodevelopmental impairment. Our study examines the association between heavy cannabis use before the onset of psychosis and clinical, neuropsychological and neurological symptoms, including NSS. In a cross-sectional study, we consecutively included 61 patients with schizophrenia (34 reporting heavy cannabis use before the onset of psychosis and 27 not reporting such use), in the setting of a University Hospital and a Medical Center. Symptoms assessment and substance use disorder were evaluated with the Diagnostic Interview for Genetic Studies. NSS were assessed with the Neurological Evaluation Scale. Psychopathology was assessed with the Positive and Negative Symptom Scale. All patients underwent a battery of neurocognitive tests evaluating attention, memory and executive functions domains. Patients with heavy cannabis use before the onset of psychosis showed significantly less NSS (p < 0.05), less negative symptoms (p < 10-3) and a better cognitive functioning in different domains [median reaction time (p = 0.03), episodic memory (p = 0.04), visuoconstructive praxs (p = 0.03) than their non-heavy user counterparts]. Confounding effects of alcohol and tobacco were taken into account. Age and gender were not statistically different between the two groups (p = 0.70 and p = 0.16, respectively). Our study supports the clinical, neuropsychological and neurological specificity associated with the heavy use of cannabis before the onset of schizophrenia. Patients with heavy cannabis use before the onset of schizophrenia may exhibit later neurodevelopmental impairment than those who do not report such use. Schizophrenia associated with heavy cannabis use could represent a specific phenotype.

Entities:  

Keywords:  Cannabis; Cognition; Neurodevelopment; Neurological soft signs; Schizophrenia

Mesh:

Year:  2017        PMID: 28190094     DOI: 10.1007/s00406-017-0767-0

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  50 in total

Review 1.  Developmental neuropathology and the precursors of schizophrenia.

Authors:  E F Walker; D Diforio; K Baum
Journal:  Acta Psychiatr Scand Suppl       Date:  1999

2.  Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.

Authors:  Louise Arseneault; Mary Cannon; Richie Poulton; Robin Murray; Avshalom Caspi; Terrie E Moffitt
Journal:  BMJ       Date:  2002-11-23

3.  The National Adult Reading Test as a measure of premorbid intelligence: a comparison with estimates derived from demographic variables.

Authors:  Peter Bright; Eli Jaldow; Michael D Kopelman
Journal:  J Int Neuropsychol Soc       Date:  2002-09       Impact factor: 2.892

4.  Fewer neurological soft signs among first episode psychosis patients with heavy cannabis use.

Authors:  Miguel Ruiz-Veguilla; Manuel Gurpegui; María Luisa Barrigón; Maite Ferrín; Esther Marín; José Luis Rubio; Blanca Gutiérrez; Antonio Pintor; Jorge Cervilla
Journal:  Schizophr Res       Date:  2008-09-21       Impact factor: 4.939

5.  The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia.

Authors:  R W Buchanan; D W Heinrichs
Journal:  Psychiatry Res       Date:  1989-03       Impact factor: 3.222

6.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

7.  Calgary Depression Scale for Schizophrenia: a study of the validity of a French-language version in a population of schizophrenic patients.

Authors:  D Bernard; C Lançon; P Auquier; G Reine; D Addington
Journal:  Acta Psychiatr Scand       Date:  1998-01       Impact factor: 6.392

8.  Neurological soft signs in schizophrenia: a meta-analysis.

Authors:  Raymond C K Chan; Ting Xu; R Walter Heinrichs; Yue Yu; Ya Wang
Journal:  Schizophr Bull       Date:  2009-04-17       Impact factor: 9.306

Review 9.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

10.  The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning.

Authors:  P D Morrison; V Zois; D A McKeown; T D Lee; D W Holt; J F Powell; S Kapur; R M Murray
Journal:  Psychol Med       Date:  2009-04-01       Impact factor: 7.723

View more
  3 in total

1.  Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.

Authors:  Musa Basseer Sami; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2018-03-29       Impact factor: 4.153

2.  Polygenic Risk Scores Shed Light on the Relationship between Schizophrenia and Cognitive Functioning: Review and Meta-Analysis.

Authors:  Jasmina Mallet; Yann Le Strat; Caroline Dubertret; Philip Gorwood
Journal:  J Clin Med       Date:  2020-01-25       Impact factor: 4.241

3.  Cannabis use in patients with early psychosis is associated with alterations in putamen and thalamic shape.

Authors:  Musa Sami; James H Cole; Matthew J Kempton; Luciano Annibale; Debasis Das; Marlene Kelbrick; Savitha Eranti; Tracy Collier; Chidimma Onyejiaka; Aisling O'Neill; David J Lythgoe; Philip McGuire; Steve C R Williams; Sagnik Bhattacharyya
Journal:  Hum Brain Mapp       Date:  2020-07-20       Impact factor: 5.399

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.